A method of treating obesity in a subject in need thereof, comprising orally administering to the subject a pharmaceutical composition comprising a crystalline form of a salt of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionic acid (OAD2), selected from the group consisting of the following:
- crystal form B of hydrochloride salt of OAD2 (form B),
- crystal form C of hydrochloride salt of OAD2 (form C),
- crystal form C of p-toluenesulfonate salt of OAD2 (form C),
- crystal form C of tartrate salt of OAD2 (form C),
- crystal form C of citrate salt of OAD2 (form C),
- crystal form C of glycollate salt of OAD2 (form C),
- crystal form C of methanesulfonate salt of OAD2 (form C),
- crystal form C of hydrobromide salt of OAD2 (form C),
- crystal form D of hydrobromide salt of OAD2 (form D), and
- crystal form C of sulfate salt of OAD2 (form C);
- and
- a pharmaceutically acceptable carrier.